Corporate Presentation Monte Rosa Corporate Presentation – March 2026 6.8 MB Presentations ASCO Genitourinary Cancers Symposium 2026 – MRT-2359 in Combination with Enzalutamide Suppresses Multiple Oncogenic Pathways to Drive Deep and Durable PSA and RECIST Responses in Heavily Pretreated, Metastatic Castration-Resistant Prostate Cancer Harbori 3.6 MB Keystone Symposia – MRT-6160, a highly selective and first-in-class VAV1-directed molecular glue degrader, demonstrates activity in multiple immune-mediated disease models 1.9 MB Nature Structural & Molecular Biology – Cereblon induces G3BP2 neosubstrate deg… MRT-8102 Phase 1 Clinical Data Update 1.1 MB MRT-2359 Phase 1/2 Clinical Data Update 1.6 MB AHA Scientific Sessions 2025 – Selective Degradation of NIMA-related kinase 7 (NEK7) via a Molecular Glue Degrader Inhibits IL-1 Downstream of NLRP3 Inflammasome Activation: A Novel Therapeutic Approach for Cardiovascular Inflammation 1.2 MB ACR Convergence 2025 – MRT-6160, a VAV1-directed molecular glue degrader, attenuates T and B cell effector functions and inhibits disease progression in a spontaneous autoimmune MRL-Faslpr mouse model 5.2 MB ECTRIMS 2025 – MRT-6160, a VAV1-Directed Molecular Glue Degrader, Inhibits Disease Progression in a Preclinical Model of T/B-cell Mediated Experimental Autoimmune Encephalomyelitis 2.6 MB Science - Mining the CRBN Target Space Redefines Rules for Molecular Glue-induc… FOCIS 2025 – MRT-6160, a VAV1-Directed Molecular Glue Degrader, Inhibits Disease Progression in a Preclinical Model of T/B-cell Mediated Experimental Autoimmune Encephalomyelitis 2.5 MB EULAR 2025 – Targeting NLRP3 Inflammasome Activation and Inflammation in Gout with NEK7 Molecular Glue Degraders: A Novel Therapeutic Strategy 1.4 MB AACR 2025 – Selective Targeting of CDK2 Using Molecular Glue Degraders for the Treatment of HR-Positive/HER2-Negative Breast Cancer 995.9 KB Monte Rosa Pipeline Update and Clinical Results Presentation (March 20, 2025) 2.7 MB Keystone Symposia – Mining the CRBN Target Space Redefines Rules of Neosubstrate Engagement 4.1 MB San Antonio Breast Cancer Symposium – Selective Targeting of CDK2 Using Molecular Glue Degraders for the Treatment of HR-Positive/HER2-Negative Breast Cancer 997.1 KB 7th Annual TPD & Induced Proximity Summit – Molecular Glue Degraders: From the Bench to the Clinic 3 MB 7th Annual TPD & Induced Proximity Summit – Rational Design of Selective CDK2 and Cyclin E1 MGDs 2.5 MB Selective Targeting of Cyclin E1 Using Molecular Glue Degraders in CCNE1 Amplified Solid Malignancies 13.3 MB 6th Annual Inflammasome Summit – Exploring Novel Modalities: Disabling the NLRP3 Inflammasome with a NEK7 Molecular Glue Degrader 2.8 MB Trends in Immunology - VAV1 as a Putative Therapeutic Target in Autoimmune and Chronic Inflammatory Diseases 1.2 MB EULAR 2024 – MRT-6160, a VAV1-Directed Molecular Glue Degrader, Reduces Joint Inflammation and Autoantibody Production in a Collagen-Induced Arthritis Autoimmune Disease Model 3.1 MB DDW 2024 – MRT-6160, a VAV1-Directed Molecular Glue Degrader, Inhibits Disease Progression in a T-cell Transfer Mediated Colitis Model Concomitant with Reduced Calprotectin Expression 1.2 MB AACR 2024 – The GSPT1 Molecular Glue Degrader MRT-2359 Is Active against Prostate Cancer 1.9 MB Molecular Glue Drug Development Summit January 2024 – Accelerating Molecular Glue Discovery Through AI/ML & Computation 8.6 MB Keystone Symposia January 2024 – Teaching CRBN New Tricks 6.3 MB ACR 2023 – A VAV1-Directed Molecular Glue Degrader, MRT-6160, Reduces Joint Inflammation in a Collagen-Induced Arthritis Autoimmune Disease Model 8.5 MB Monte Rosa Company Call Presentation - October 17 2023 1.8 MB AACR 2023 - Development of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for the treatment of lung cancers with MYC-induced translational addiction 4.3 MB AACR 2023 - Discovery of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for MYC-driven cancers 4.4 MB MRT-2359 KOL Webinar, October 24, 2022 4.5 MB 34th EORTC-NCI-AACR Symposium 4.1 MB 5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359 5.1 MB 5th Annual TPD Summit - AI Applications for Molecular Glue Degraders 9.2 MB American Association for Cancer Research Annual Meeting, April 8-13, 2022 1 MB 2nd Annual TPD Europe Summit Presentation 3.9 MB 4th Annual Targeted Protein Degradation Summit Presentation 4.8 MB AACR-NCI-EORTC Late Breaking Presentation 2.1 MB European Protein Degradation Congress 2021 Presentation 3.8 MB
ASCO Genitourinary Cancers Symposium 2026 – MRT-2359 in Combination with Enzalutamide Suppresses Multiple Oncogenic Pathways to Drive Deep and Durable PSA and RECIST Responses in Heavily Pretreated, Metastatic Castration-Resistant Prostate Cancer Harbori 3.6 MB
ASCO Genitourinary Cancers Symposium 2026 – MRT-2359 in Combination with Enzalutamide Suppresses Multiple Oncogenic Pathways to Drive Deep and Durable PSA and RECIST Responses in Heavily Pretreated, Metastatic Castration-Resistant Prostate Cancer Harbori 3.6 MB
Keystone Symposia – MRT-6160, a highly selective and first-in-class VAV1-directed molecular glue degrader, demonstrates activity in multiple immune-mediated disease models 1.9 MB
Keystone Symposia – MRT-6160, a highly selective and first-in-class VAV1-directed molecular glue degrader, demonstrates activity in multiple immune-mediated disease models 1.9 MB
AHA Scientific Sessions 2025 – Selective Degradation of NIMA-related kinase 7 (NEK7) via a Molecular Glue Degrader Inhibits IL-1 Downstream of NLRP3 Inflammasome Activation: A Novel Therapeutic Approach for Cardiovascular Inflammation 1.2 MB
AHA Scientific Sessions 2025 – Selective Degradation of NIMA-related kinase 7 (NEK7) via a Molecular Glue Degrader Inhibits IL-1 Downstream of NLRP3 Inflammasome Activation: A Novel Therapeutic Approach for Cardiovascular Inflammation 1.2 MB
ACR Convergence 2025 – MRT-6160, a VAV1-directed molecular glue degrader, attenuates T and B cell effector functions and inhibits disease progression in a spontaneous autoimmune MRL-Faslpr mouse model 5.2 MB
ACR Convergence 2025 – MRT-6160, a VAV1-directed molecular glue degrader, attenuates T and B cell effector functions and inhibits disease progression in a spontaneous autoimmune MRL-Faslpr mouse model 5.2 MB
ECTRIMS 2025 – MRT-6160, a VAV1-Directed Molecular Glue Degrader, Inhibits Disease Progression in a Preclinical Model of T/B-cell Mediated Experimental Autoimmune Encephalomyelitis 2.6 MB
ECTRIMS 2025 – MRT-6160, a VAV1-Directed Molecular Glue Degrader, Inhibits Disease Progression in a Preclinical Model of T/B-cell Mediated Experimental Autoimmune Encephalomyelitis 2.6 MB
FOCIS 2025 – MRT-6160, a VAV1-Directed Molecular Glue Degrader, Inhibits Disease Progression in a Preclinical Model of T/B-cell Mediated Experimental Autoimmune Encephalomyelitis 2.5 MB
FOCIS 2025 – MRT-6160, a VAV1-Directed Molecular Glue Degrader, Inhibits Disease Progression in a Preclinical Model of T/B-cell Mediated Experimental Autoimmune Encephalomyelitis 2.5 MB
EULAR 2025 – Targeting NLRP3 Inflammasome Activation and Inflammation in Gout with NEK7 Molecular Glue Degraders: A Novel Therapeutic Strategy 1.4 MB
EULAR 2025 – Targeting NLRP3 Inflammasome Activation and Inflammation in Gout with NEK7 Molecular Glue Degraders: A Novel Therapeutic Strategy 1.4 MB
AACR 2025 – Selective Targeting of CDK2 Using Molecular Glue Degraders for the Treatment of HR-Positive/HER2-Negative Breast Cancer 995.9 KB
AACR 2025 – Selective Targeting of CDK2 Using Molecular Glue Degraders for the Treatment of HR-Positive/HER2-Negative Breast Cancer 995.9 KB
San Antonio Breast Cancer Symposium – Selective Targeting of CDK2 Using Molecular Glue Degraders for the Treatment of HR-Positive/HER2-Negative Breast Cancer 997.1 KB
San Antonio Breast Cancer Symposium – Selective Targeting of CDK2 Using Molecular Glue Degraders for the Treatment of HR-Positive/HER2-Negative Breast Cancer 997.1 KB
7th Annual TPD & Induced Proximity Summit – Molecular Glue Degraders: From the Bench to the Clinic 3 MB
7th Annual TPD & Induced Proximity Summit – Molecular Glue Degraders: From the Bench to the Clinic 3 MB
7th Annual TPD & Induced Proximity Summit – Rational Design of Selective CDK2 and Cyclin E1 MGDs 2.5 MB
7th Annual TPD & Induced Proximity Summit – Rational Design of Selective CDK2 and Cyclin E1 MGDs 2.5 MB
Selective Targeting of Cyclin E1 Using Molecular Glue Degraders in CCNE1 Amplified Solid Malignancies 13.3 MB
Selective Targeting of Cyclin E1 Using Molecular Glue Degraders in CCNE1 Amplified Solid Malignancies 13.3 MB
6th Annual Inflammasome Summit – Exploring Novel Modalities: Disabling the NLRP3 Inflammasome with a NEK7 Molecular Glue Degrader 2.8 MB
6th Annual Inflammasome Summit – Exploring Novel Modalities: Disabling the NLRP3 Inflammasome with a NEK7 Molecular Glue Degrader 2.8 MB
Trends in Immunology - VAV1 as a Putative Therapeutic Target in Autoimmune and Chronic Inflammatory Diseases 1.2 MB
Trends in Immunology - VAV1 as a Putative Therapeutic Target in Autoimmune and Chronic Inflammatory Diseases 1.2 MB
EULAR 2024 – MRT-6160, a VAV1-Directed Molecular Glue Degrader, Reduces Joint Inflammation and Autoantibody Production in a Collagen-Induced Arthritis Autoimmune Disease Model 3.1 MB
EULAR 2024 – MRT-6160, a VAV1-Directed Molecular Glue Degrader, Reduces Joint Inflammation and Autoantibody Production in a Collagen-Induced Arthritis Autoimmune Disease Model 3.1 MB
DDW 2024 – MRT-6160, a VAV1-Directed Molecular Glue Degrader, Inhibits Disease Progression in a T-cell Transfer Mediated Colitis Model Concomitant with Reduced Calprotectin Expression 1.2 MB
DDW 2024 – MRT-6160, a VAV1-Directed Molecular Glue Degrader, Inhibits Disease Progression in a T-cell Transfer Mediated Colitis Model Concomitant with Reduced Calprotectin Expression 1.2 MB
Molecular Glue Drug Development Summit January 2024 – Accelerating Molecular Glue Discovery Through AI/ML & Computation 8.6 MB
Molecular Glue Drug Development Summit January 2024 – Accelerating Molecular Glue Discovery Through AI/ML & Computation 8.6 MB
ACR 2023 – A VAV1-Directed Molecular Glue Degrader, MRT-6160, Reduces Joint Inflammation in a Collagen-Induced Arthritis Autoimmune Disease Model 8.5 MB
ACR 2023 – A VAV1-Directed Molecular Glue Degrader, MRT-6160, Reduces Joint Inflammation in a Collagen-Induced Arthritis Autoimmune Disease Model 8.5 MB
AACR 2023 - Development of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for the treatment of lung cancers with MYC-induced translational addiction 4.3 MB
AACR 2023 - Development of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for the treatment of lung cancers with MYC-induced translational addiction 4.3 MB
AACR 2023 - Discovery of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for MYC-driven cancers 4.4 MB
AACR 2023 - Discovery of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for MYC-driven cancers 4.4 MB